IE 11 is a very old browser and is not supported on this site.
Management report - Introduction


Management report

The Galenica Group can look back on an extremely successful financial year 2021: consolidated net sales increased by 10.2% to CHF 3,834.7 million and the adjusted¹ operating result (EBIT) increased by 26.4% to CHF 213.1 million. The Board of Directors will propose to the Annual General Meeting a dividend of CHF 2.10 (+17%), of which CHF 1.05 will be paid from the capital contribution reserve.

Highlights from the financial year 2021

Primary Care


Offers in pharmacies

Online shops


Sales growth



Vaccinations in Galenica Group pharmacies

This sales development was driven in particular by one-off additional sales in connection with COVID-19. The business developed very dynamically, especially in the last few months of 2021. On the one hand, the one-off additional sales in relation to COVID-19 increased again, and on the other hand, the sales of cold and flu medicines went up sharply compared to the same period of the previous year. A strong performance by the Mediservice speciality pharmacy and further market share gains in the wholesale business with physicians also contributed positively to sales growth. Once again, acquisitions of companies and products were another growth driver in the 2021 financial year. The profit from the sale of the property at the Galenica headquarters in Bern also had a positive impact on EBIT.

1) Excluding the effects of IAS 19 and IFRS 16. See chapter «Alternative performance measures».

Highlights from the financial year 2021

  • As of the end of 2021, more than 230,000 antigen, PCR and antibody tests and over 90,000 vaccinations were carried out in Galenica Group pharmacies.
  • With 28 primary care offers, the importance of pharmacies as the first point of contact for health issues increased further.
  • The linking of online and offline offers gained further momentum, for example with the online booking of test and vaccination services.
  • Online sales at Amavita and Sun Store grew by 50%.
  • The speciality pharmacy Mediservice saw excellent growth with new medicines for rare diseases in combination with the increasing demand for home care services.
  • New and existing partnerships with healthcare providers strengthened the offering available to business (B2B) and end (B2C) customers.
  • Verfora reinforced its leading position in the Swiss consumer healthcare market through acquisitions.
  • Galexis gained more market share with new offers for specialist doctors and the support of medical centres.
Galenica uses cookies to optimise the functions of the website and to ensure you enjoy the best possible experience. Use of cookies & disclaimer